ACB Is Attractive but There Are Compelling Reasons to Buy HEXO Stock

After a tumultuous period late-last year, publicly-traded marijuana companies have once again captured the limelight. Among the extensive options investors have, two names, Hexo (AMEX:HEXO) and Aurora Cannabis (NYSE:ACB), piqued most people’s interest. The question now is, should investors gamble on HEXO stock or take the more proven ACB?

Source: Shutterstock

On surface level, both companies feature similar characteristics. Primarily, the two cannabis rivals have outperformed in the markets so far this year. Even their performance stats are neck-and-neck. For instance, on a year-to-date basis, ACB stock is up slightly over 80%, while Hexo has skyrocketed over 86%.

In addition, both organizations call Canada home, and obviously both are attempting to capture their home country’s market share. From an investor psychology perspective, HEXO stock and ACB stock have similar price points. Therefore, they both appeal to the same category of speculators looking to make a quick buck.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

• 10 Dow Jones Stocks Holding the Blue Chip Index Back

Finally, the two companies specialize in cannabidiol, or CBD. This typically non-psychoactive compound derived from the cannabis sativa plant offers health benefits but without marijuana’s addictive properties. A CBD revolution alone could drive either Hexo stock or ACB to the moon.

Still, does anything distinguish them? Let’s take a deeper look, beginning with HEXO stock:

CBD-Infused HEXO Stock Has Potential

Like other weed firms, analysts mostly focus on production capacity when discussing HEXO stock. Luckily, management recognizes this and have responded accordingly. Last month, Hexo made headlines when it acquired Newstrike Brands in an all-equity transaction.

Valued at $263 million, the deal gives the acquiring company 470,000 square feet of production space. With the additional capacity, this could boost revenue to $400 million by July of next year. For context, Hexo’s trailing-twelve month (TTM) revenue is $16.5 million.

But what really intrigues me about HEXO stock is its joint venture with Molson Coors Brewing (NYSE:TAP). Together, the two will develop non-alcoholic, CBD-infused beverages for the Canadian market.

Aside from the numbers, the deal is similar in principle with Altria Group’s (NYSE:MO) investment in Cronos Group (NASDAQ:CRON). Both Molson and Altria recognized the growing trend in CBD and legal marijuana, and jumped at the opportunity to partner with key players in the segment.

However, Molson’s venture is more promising because CBD beverages are an inoffensive way to consume botanicals. Unless you’re peeing on your neighbor, there’s no reason why anyone would complain about someone drinking cannabidiol.

On the other hand, smoking or vaping the stuff is inherently offensive. Altria and Cronos will have to figure out a way to mainstream their CBD platform. But for Molson and HEXO stock, the opportunity is turnkey so long as legal momentum continues its path.

Smart Strategies Bolster ACB Stock

As I mentioned earlier, most analysts who cover marijuana firms focus extensively on production capacity. This emphasis makes perfectly logical sense. After all, you can’t take market share if you don’t have any supply to feed demand.

This is one of the reasons why several critics blasted ACB stock when the underlying company acquired Whistler Medical Marijuana. While Aurora Cannabis bought out several other production facilities, the Whistler deal raised eyebrows for the wrong reason. With an annual production capacity of only 5,000 kilograms, this figure paled in comparison to the usual six-figure digits.

So why Whistler? Because this is a company that specializes in differentiated cannabis products. A particular factor driving ACB stock is that its management team is smart. They know that the low-hanging fruit in this segment is gone. Currently, the industry emphasizes capacity. But later down the road, customers will seek distinctive products.